European regulators and health experts have recommended a second booster dose of mRNA COVID-19 vaccines for people between 60 and 79 years of age and for vulnerable people with medical conditions, as Moderna Inc. filed fresh data from its omicron subvariant-adapted shot.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Inventiva, Moleculin, Myrtelle, Optinose, Regenxbio.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alimera, Horizon, MGC, Puma, Siga.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aditxt, Emergent, Entasis, F-star, Innoviva, La Jolla, Novavax, Rational, Ridgeback, Sino, Vertex.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Empowered Diagnostics.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Dexcom, Electrocore, Laseroptek, Medial Earlysign, Reflexion, Roche, Zillion.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adverum, Annovis, Bausch + Lomb, Clovis, Diamedica, Innocare, Pfizer, Xortx.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascletis, Biogen, Chinook, Coherus, Junshi, Inflarx, Kazia, Olix, Pyramid, Roche, Sensorion, Takeda, Titan, Turnstone.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Gnubiotics, Homology, Immunome, Intravacc, Kalvista, Kamada, Mnemo, Pfizer, Plakous, Ring, Roivant, Sollievo, Touchlight, Turnstone, Vast, Walden.
RSS
